Key result
A 67-year-old male developed a subacute left ventricular free wall rupture with frank pericardial effusion after receiving thrombolytic and glycoprotein IIb/IIIa inhibitor therapies for acute myocardial infarction.
Case Report (n=1)
No
The combination of thrombolytic therapy and glycoprotein IIb/IIIa inhibitors in acute myocardial infarction may increase the risk of subacute left ventricular free wall rupture, highlighting the need for careful echocardiographic monitoring.
May signal higher rupture risk with combined thrombolysis and GP IIb/IIIa post-MI; hypothesis-generating and should not yet change practice.
Subacute left ventricular free wall rupture is a rare complication in acute myocardial infarction. With the increasing use of thrombolytic agents and glycoprotein IIb/IIIa inhibitors, this complication has been increasing recently. We report a case of subacute cardiac rupture with frank pericardial effusion receiving thrombolytic and glycoprotein IIb/IIIa inhibitor therapies.
No takes yet. Share an insight, caveat, or question.
Altunkeser et al. (2002) conducted a case report in Acute myocardial infarction (n=1). Thrombolytic (streptokinase) and glycoprotein IIb/IIIa inhibitor (tirofiban) was evaluated on Subacute left ventricular free wall rupture. A 67-year-old male developed a subacute left ventricular free wall rupture with frank pericardial effusion after receiving thrombolytic and glycoprotein IIb/IIIa inhibitor therapies for acute myocardial infarction.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: